Clinuvel Pharmaceuticals (ASX:CUV) Valuation Check As VLRX L Preclinical Milestone Expands Pipeline Potential

Simply Wall St.

Jan 15

Clinuvel Pharmaceuticals (ASX:CUV) has started dosing patients in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform. This marks its first next-generation delivery...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603545606"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603545606\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603545606?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-15 15:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603545606","market":"nz","top_or_hot":-1,"title":"Clinuvel Pharmaceuticals (ASX:CUV) Valuation Check As VLRX L Preclinical Milestone Expands Pipeline Potential","media":"Simply Wall St.","content":"<div>\n<p>Clinuvel Pharmaceuticals (ASX:CUV) has started dosing patients in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform. This marks its first next-generation delivery...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-as-vlrx-l-pr\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinuvel Pharmaceuticals (ASX:CUV) Valuation Check As VLRX L Preclinical Milestone Expands Pipeline Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinuvel Pharmaceuticals (ASX:CUV) Valuation Check As VLRX L Preclinical Milestone Expands Pipeline Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-15 15:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-as-vlrx-l-pr><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Clinuvel Pharmaceuticals (ASX:CUV) has started dosing patients in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform. This marks its first next-generation delivery...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-as-vlrx-l-pr\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CUV.AU","symbol_name":"CLINUVEL PHARMACEUTICALS LTD","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-as-vlrx-l-pr","article_id":"2603545606","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-as-vlrx-l-pr","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603545606","pubTimestamp":1768462462,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Clinuvel Pharmaceuticals (ASX:CUV) has started dosing patients in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform. This marks its first next-generation delivery technology to enter formal preclinical testing.\nSee our latest analysis for Clinuvel Pharmaceuticals.\nThe VLRX-L preclinical milestone comes as the share price sits at A$12.75, with a 1-day share price return of 4.25% and a 90-day share price return of 10.29%, while the 1-year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CUV.AU":"CLINUVEL PHARMACEUTICALS LTD","VLRX":"Valeritas Holdings, Inc.","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"随着VLRX L临床前里程碑扩大管道潜力，Clinuvel Pharmaceuticals(ASX：CUV)估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VLRX":1.5,"CUV.AU":1.5},"content_text":"Clinuvel Pharmaceuticals (ASX:CUV) has started dosing patients in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform. This marks its first next-generation delivery technology to enter formal preclinical testing. See our latest analysis for Clinuvel Pharmaceuticals. The VLRX-L preclinical milestone comes as the share price sits at A$12.75, with a 1-day share price return of 4.25% and a 90-day share price return of 10.29%, while the 1-year total shareholder return is 8.66%. However, the three and five year total shareholder returns remain negative, suggesting recent momentum is improving after a tougher period for longer term holders. If this kind of pipeline progress has caught your eye, it can be worth scanning other specialised names in the space through healthcare stocks to see what else fits your watchlist. With A$95.02m in revenue, A$36.17m in net income and the share price trading at a large discount to both analyst targets and some intrinsic estimates, you have to ask: is Clinuvel undervalued, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 46.6% Undervalued At A$12.75, the most followed narrative sees Clinuvel trading well below its A$23.87 fair value estimate, with that gap hinging on future growth and margins. Significant reinvestment of profits into R&D (20% of revenue) and communications/marketing, facilitated by strong free cash flow and a large cash reserve, positions the company to advance multiple programs in parallel without need for shareholder dilution. This is viewed as supporting future earnings power and reducing funding risk, which is considered undervalued by the market. Read the complete narrative. Curious what kind of revenue ramp, margin profile, and future earnings multiple are baked into that fair value? The narrative leans on punchy growth forecasts and a richer profit mix that may surprise you when you see the actual assumptions. Result: Fair Value of A$23.87 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on SCENESSE remaining resilient and pipeline assets gaining traction. Any competitive pressure or regulatory setback could quickly challenge that undervalued story. Find out about the key risks to this Clinuvel Pharmaceuticals narrative. Another View on Clinuvel's Valuation That 46.6% undervalued narrative leans on future cash flows and growth assumptions, but the current P/E of 17.7x tells a more mixed story. It sits above peers at 16.1x and above the fair ratio of 15.6x, which points to less of a clear-cut bargain and more valuation risk if growth underwhelms. Put simply, the share price already asks you to pay a premium to similar companies and to where the fair ratio suggests it could settle. The key question is whether you think future execution comfortably justifies that extra stretch. See what the numbers say about this price — find out in our valuation breakdown. ASX:CUV P/E Ratio as at Jan 2026 Build Your Own Clinuvel Pharmaceuticals Narrative If you see the numbers differently, or prefer to test the assumptions yourself, you can build a custom view in just a few minutes with Do it your way. A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Clinuvel Pharmaceuticals. Looking for more investment ideas? Before you move on, give yourself a broader watchlist by scanning a few focused stock groups that could complement or challenge your view on Clinuvel.  Target potential bargains by checking these 883 undervalued stocks based on cash flows that match your preferred mix of quality, price and future prospects. Ride long term technology shifts by reviewing these 25 AI penny stocks that are building real businesses around artificial intelligence. Strengthen your income options by lining up these 12 dividend stocks with yields > 3% that may offer more dependable cash returns.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}